Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 19/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 0.69 |
| ▸ | CCNH | P51946 | 2/20 | 0.69 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.69 |
| ▸ | PLK4 | O00444 | 1/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.69 |
| ▸ | AURKA | O14965 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.69 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.69 |
| ▸ | STK16 | O75716 | 1/20 | 0.69 |
| ▸ | PAK3 | O75914 | 1/20 | 0.69 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | LATS1 | O95835 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | PRKCG | P05129 | 1/20 | 0.69 |
| ▸ | PRKCB | P05771 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942571 | 0.89 | PAK4 (0.80) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1941916 | 0.88 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1369668 | 0.88 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL10321436 | 0.87 | PAK4 (0.78) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL10321435 | 0.87 | PAK4 (0.78) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1369692 | 0.87 | PAK4 (1.00) | PAK4MAPK1GSK3BCDK2 | |
| SCHEMBL1369694 | 0.87 | PAK4 (1.00) | PAK4MAPK1GSK3BCDK2 | |
| SCHEMBL1367121 | 0.84 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1940868 | 0.83 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1943421 | 0.82 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | claimed |
| US-20150031693-A1 | PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME | AFRAXIS HOLDINGS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8067591-B2 | Pyrrolopyrazole, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067591-B2 | Pyrrolopyrazole, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067591-B2 | Pyrrolopyrazole, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1838718-B1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | disclosed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | disclosed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116263-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | PAK2, PAK3, PAK1 | PAK4 5/4885CDK7 147/4885CCNH 108/4885 |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | PAK4 1/4885CDK7 224/4885CCNH 1937/4885 |
| US-20150031693-A1 | PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME | PAK5, PAK2, PAK4 | PAK4 3/4885CDK7 1014/4885CCNH 2632/4885 |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | PAK4 1/4885CDK7 228/4885CCNH 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.